Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PARG | Q86W56 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025231 | 0.94 | KMT2A (0.65) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL2195916 | 0.93 | KMT2A (0.64) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL2195922 | 0.93 | KMT2A (0.64) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL24496063 | 0.87 | KMT2A (0.73) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL16378516 | 0.85 | KMT2A (0.55) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL17765473 | 0.85 | KMT2A (0.55) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL17765475 | 0.85 | KMT2A (0.55) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL2372122 | 0.81 | ALDH1A1 (0.65) | KMT2ATDP1POLBKDM4ERECQL | |
| SCHEMBL27225135 | 0.80 | KMT2A (0.48) | KMT2ATDP1POLBSMN1; SMN2HTT | |
| SCHEMBL30817511 | 0.80 | KMT2A (0.48) | KMT2ATDP1POLBHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4232023-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3724180-B1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA FARBER CANCER INST INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022093742-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | KMT2A 1642/4885TDP1 902/4885POLB 2538/4885 |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | KMT2A 399/4885TDP1 4589/4885POLB 4582/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | KMT2A 279/4885TDP1 4486/4885POLB 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.